

ANTIDIABETIC ACTION OF SOME MEDICINAL PLANTS

(REVIEW OF RECENT 15 YEARS PUBLICATION)

© T. V. Yakimova, O. N. Nasanova, A. I. Vengerovsky¹

Siberian State Medical University, Tomsk, Russia

¹E-mail: pharm-sibgmu@rambler.ru

REFERENCES

1. Jung M., Park M., Lee H. C., Kang Y. H., Kang E. S., Kim S. K. 2006. Antidiabetic agent from medicinal plants. — *Curr. Med. Chem.* 13(10): 1203–1218.
2. Patel R., Kumar D., Laloo S., Hemalatha D. K. 2012. Natural medicines from plant source used for therapy of diabetes mellitus: An overview of its pharmacological aspects. — *Asian Pacif. J. Trop. Dis.* 2(3): 239–250.
3. Perla V., Jayanty S. S. 2013. Biguanide related compounds in traditional antidiabetic functional foods. — *Food Chem.* 138(23): 1574–1580.
4. Jamila F., Mostafa E. 2014. Ethnobotanical survey of medicinal plants used by people in Oriental Morocco to manage various ailments. — *J. Ethnopharmacol.* 154(1): 76–87.
5. Bnouham M., Merhfouf F. Z., Ziyat A., Aziz M., Legssyer A., Mekhfi H. 2010. Antidiabetic effect of some medicinal plants of Oriental Morocco in neonatal non-insulin-dependent diabetes mellitus rats. — *Hum. Exp. Toxicol.* 29(10): 865–871.
6. Said O., Fulder S., Khalil K., Azaizeh H., Kassis E., Saad B. 2008. Maintaining a physiological blood glucose level with glucolevel, a combination of four antidiabetes plants used in the traditional arab herbal medicine. — *Evid. Based. Complement. Alternat. Med.* 5(4): 421–428.
7. Deng R. 2012. A review of the hypoglycemic effects of five commonly used herbal food supplements. — *Recent. Pat. Food Nutr. Agric.* 4(1): 50–60.
8. Osmanova N. A., Prjakhina N. I. 2003. Some pharmacological properties of above-ground part of *Galega officinalis* L. and *G. orientalis* Lam. — *Rastitelnye resursy.* 39(4): 119–129. (In Russian)
9. Azhunova T. A., Markizov P. V. 1994. Antidiabetic activity of *Galega officinalis*. *Khimico-farmatsevticheskiy zhurnal.* 28(6): 35–36. (In Russian)
10. Yakimova T. V., Nasanova O. N., Vengerovsky A. I., Burkova V. N. 2011. Influence of *Galega* extract on lipids metabolism in experimental diabetes mellitus. — *Sibirskiy meditsinskiy zhurnal.* 26,4 (2): 98–102. (In Russian)
11. Kit S. M., Turchin I. S. 1986. *Lekarstvennye rasteniya v endocrinologii* [Medicinal herbs in endocrinology]. Kiev. 78 p. (In Russian)
12. Cao J., Li C., Zhang P., Cao X., Huang T., Bai Y., Chen K. 2012. Antidiabetic effect of burdock (*Arctium lappa* L.) root ethanolic extract on streptozotocin-induced diabetic rats. — *Afr. J. Biotechnol.* 11(37): 9079–9085.
13. Huang S. L., Yu R. T., Gong J., Feng Y., Dai Y. L., Hu F., Hu Y. H., Tao Y. D., Leng Y. 2012. Arctigenin, a natural compound, activates AMP-activated protein kinase via inhibition of mitochondria complex I and ameliorates metabolic disorders in ob/ob mice. — *Diabetologia.* 55(5): 1469–1481.
14. Xu Z., Wang X., Zhou M., Ma L., Deng Y., Zhang H., Zhao A., Zhang Y., Jia W. 2008. The antidiabetic activity of total lignan from fructus *Arctii* against alloxan-induced diabetes in mice and rats. *Phytother. Res.* 22(1): 97–101.

15. Xu Z., Ju J., Wang K., Gu C., Feng Y. 2014. Evaluation of hypoglycemic activity of total lignans from fructus *Arctii* in the spontaneously diabetic Goto—Kakizaki rats. — *J. Ethnopharmacol.* 151(1): 548—555.
16. Okada Y., Okada M., Sagesaka Y. 2010. Screening of dried plant seed extracts for adiponectin production activity and tumor necrosis factor-alpha inhibitory activity on 3T3-L1 adipocytes. — *Plant Foods Hum. Nutr.* 65(3): 225—232.
17. Miyazawa M., Yagi N., Taguchi K. 2005. Inhibitory compounds of α -glucosidase activity from *Arctium lappa* L. — *J. Oleo Sci.* 54(11): 589—594.
18. Tang X., Zhuang J., Chen J., Yu L., Hu L., Jiang H., Shen X. Arctigenin efficiently enhanced sedentary mice treadmill endurance. — *PLoS One.* 2011. [http://www.plosone.org/article/info %3Adoi %2F10.1371 %2 Fjournal.pone.0024224](http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0024224)
19. Ma S. T., Liu D. L., Deng J. J., Niu R., Liu R. B. 2013. Effect of arctiin on glomerular filtration barrier damage in STZ-induced diabetic nephropathy rats. — *Phytother. Res.* 27(10): 1474—1480.
20. Lu L. C., Zhou W., Li Z. H., Yu C. P., Li C. W., Luo M. H., Xie H. 2012. Effects of arctiin on streptozotocin-induced diabetic retinopathy in Sprague-Dawley rats. — *Planta Med.* 78(12): 1317—1323.
21. Bnouham M., Merhfour F. Z., Ziyat A., Mekhfi H., Aziz M., Legssyer A. 2003. Antihyperglycemic activity of the aqueous extract of *Urtica dioica*. — *Fitoterapia.* 74(8): 677—681.
22. Das M., Sarma B. P., Rokeya B., Parial R., Nahar N., Mosihuzzaman M., Khan A., Ali L. 2011. Antihyperglycemic and antihyperlipidemic activity of *Urtica dioica* on type 2 diabetic in model rats. — *J. Diabetol.* 2(2): 16—20.
23. Domola M. S., Vu V., Robson-Doucette C. A., Sweeney G., Wheeler M. B. Insulin mimetics in *Urtica dioica*: structural and computational analyses of *Urtica dioica* extracts. — *Phytother. Res.* 2010. Vol. 24, N 2. P. 175—182.
24. Golalipour M. J., Khor V. 2007. The protective activity of *Urtica dioica* leaves on blood glucose concentration and β -cells in streptozotocin-diabetic rats. — *Pak. J. Biol. Sci.* 10(8): 1200—1204.
25. Qued D., Tatar M., Feizi F. 2013. Effect of *Urtica dioica* leaf alcoholic and aqueous extracts on the number and the diameter of the islets in diabetic rats. — *Int. J. Mol. Cell. Med.* 2(1): 21—26.
26. Kadan S., Saad B., Sasson Y., Zaid H. 2013. *In vitro* evaluations of cytotoxicity of eight antidiabetic medicinal plants and their effect on GLUT4 translocation. — *Evid. Based. Complement. Alternat. Med.* <http://dx.doi.org/10.1155/2013/549345>
27. Patel S. S., Udayabanu M. 2014. *Urtica dioica* extract attenuates depressive like behavior and associative memory dysfunction in dexamethasone induced mice. — *Metab. Brain Dis.* 29(1): 121—130.
28. Patel S. S., Udayabanu M. 2013. Effect of *Urtica dioica* on memory dysfunction and hypoalgesia in an experimental model of diabetic neuropathy. — *Neurosci. Lett.* 552(1): 114—119.
29. Jahanshahi M., Golalipour M. J., Afshar M. 2009. The effect of *Urtica dioica* extract on the number of astrocytes in the dentate gyrus of diabetic rats. — *Folia Morphol.* 68(2): 93—97.
30. Nickavar B., Yousefian N. 2011. Evaluation of α -amylase inhibitory activities of selected antidiabetic medicinal plants. — *J. Verbr. Lebensm.* 6(2): 191—195.
31. Rahimzadeh M., Jahanshahi S., Moein S., Moein M. R. 2014. Evaluation of α -amylase inhibition by *Urtica dioica* and *Juglans regia* extracts. — *Iran. J. Basic Med. Sci.* 17(6): 465—469.
32. Golalipour M. J., Gharravi A. M., Grafari S., Afshar M. 2007. Effect of *Urtica dioica* on morphometric indices of kidney in streptozotocin-diabetic rats a stereological study. — *Pak. J. Biol. Sci.* 10(21): 3875—3879.
33. Rau O., Wurglics M., Dingermann T., Abdel-Tawab M., Schubert-Zsilavecz M. 2006. Screening of herbal extracts for activation of the human peroxisome proliferator-activated receptor. — *Pharmacy.* 61(11): 952—956.

34. Namazi N., Esfanjani A. T., Heshmati J., Bahrami A. 2011. The effect of hydroalcoholic nettle (*Urtica dioica*) extracts on insulin sensitivity and some inflammatory indicators in patients with type 2 diabetes: a randomized double-blind control trial. — Pak. J. Biol. Sci. 14(15): 775—779.
35. Namazi N., Tarighat A., Bahrami A. 2012. The effect of hydroalcoholic nettle (*Urtica dioica*) extract on oxidative stress in patients with type 2 diabetes: a randomized double-blind clinical trial. — Pak. J. Biol. Sci. 15(2): 98—102.
36. Vaidya S. 2011. Review on *Gymnema*: an herbal medicine for diabetes management. — Pharmacia. 1(2): 37—42.
37. Fabio G. D., Romanucci V., De Marco A., Zarrelli A. 2014. Triterpenoids from *Gymnema sylvestre* and their pharmacological activities. — Molecules. 19(8): 10 956—10 981.
38. Pothuraju R., Sharma R. K., Chagalamarri J., Jangra S., Kumar K. P. 2014. A systematic review of *Gymnema sylvestre* in obesity and diabetes management. — J. Sci. Food Agric. 94(5): 834—840.
39. Tiwari P., Mishra B. N., Sangwan N. S. 2014. Phytochemical and pharmacological properties of *Gymnema sylvestre*: an important medicinal plant. — Biomed. Res. Int. Art. ID 830285.
40. Voronkova M. P. 2009. Protivodiabeticheskaya aktivnost gimnenoviyh kislot: Avtoref. dis. ... doct. biol. nauk. [Antidiabetic activity of gymnemic acids: Abstr. ... Diss. Doct. (Biology) Sci.]. Volgograd. 46 p. (In Russian)
41. Wang Y., Dawid C., Kottra G., Daniel H., Hofmann T. 2014. Gymnemic acids inhibit sodium-dependent glucose transporter 1. — J. Agric. Food. Chem. 62(25): 5925—5931.
42. Spasov A. A., Bulanov A. E., Samokhina M. P. 2008. Antidiabetic properties of *Gymnema sylvestre*. — Khimico-farmatsevtichesky Zhurnal. 42(11): 10—14. (In Russian)
43. Kosaraju J., Dubala A., Chinni S., Khatwal R. B., Kumar M. N., Basavan D. 2014. A molecular connection of *Pterocarpus marsupium*, *Eugenia jambolana* and *Gymnema sylvestre* with dipeptidyl peptidase-4 in the treatment of diabetes. — Pharm. Biol. 52(2): 268—271.
44. Al-Romaiyan A., King A. J., Persaud S. J., Jones P. M. 2013. Anovel extract of *Gymnema sylvestre* improves glucose tolerance in vivo and stimulates insulin secretion *in vitro*. — Phytother. Res. 27 (7): 1006—1011.
45. Liu B., Asare-Anane H., Al-Romaiyan A., Huang G., Amiel S. A., Jones P. M., Persaud S. J. 2009. Characterization of the insulinotropic activity of an aqueous extract of *Gymnema sylvestre* in mouse b-cells and human islets of Langerhans. — Cell. Physiol. Biochem. 23(1—3): 125—132.
46. Al-Romaiyan A., Liu B., Docherty R., Huang G. C., Amiel S., Persaud S. J., Jones P. M. 2012. Investigation of intracellular signaling cascades mediating stimulatory effect of a *Gymnema sylvestre* extract on insulin secretion from isolated mouse and human islets of Langerhans. — Diabetes Obes. Metab. 14(12): 1104—1113.
47. Luo H., Kashiwagi A., Shibahara T., Yamada K. 2007. Decreased bodyweight without rebound and regulated lipoprotein metabolism by gymnemate in genetic multifactor animal syndrome. — Mol. Cell. Biochem. 299(1—2): 93—98.
48. Mall G. K., Mishra P. K., Prakash V. 2009. Antidiabetic and hypolipidemic activity of *Gymnema sylvestre* in alloxan-induced diabetic rats. Global J. Biotech. Biochem. 4(1): 37—42.
49. Rachh R., Rachh M. R., Ghadiya N. R., Modi D. C., Patel N. M., Rupareliya M. T. 2010. Antihyperlipidemic activity of *Gymnema sylvestre* R. Br. leaf extract on rats fed with high cholesterol diet. — Int. J. Pharmacol. 6(2): 138—141.
50. Kaushik M., Kaushik A., Arya R., Singh G., Malik P. 2011. Anti-obesity property of hexane extract from the leaves of *Gymnema sylvestre* in high fed cafeteria diet induced obesity rats. — Int. Res. J. Pharm. 2(8): 112—116.
51. Prabhu S., Vijayakumar S. 2014. Antidiabetic, hypolipidemic and histopathological analysis of *Gymnema sylvestre* (R. Br.) leaves extract on streptozotocin induced diabetic rats. Biomed. Prevent. Nutr. 4(3): 425—430.

52. Rahman M. M., Habib M. R., Hasan M. A., Al Amin M., Saha A., Mannan A. 2014. Comparative assessment on *in vitro* antioxidant activities of ethanol extracts of *Averrhoa bilimbi*, *Gymnema sylvestre* and *Capsicum frutescens*. — Pharmacogn. Res. 6(1): 36—41.
53. Kang M. H., Lee M. S., Choi M. K., Min K. S., Shibamoto T. 2012. Hypoglycemic activity of *Gymnema sylvestre* extracts on oxidative stress and antioxidant status in diabetic rats. — J. Agric. Food Chem. 60(10): 2517—2524.
54. Singh J., Cumming E., Manoharan G., Kalasz H., Adeghate E. 2011. Medicinal chemistry of the antidiabetic effects of *Momordica charantia*: active constituents and modes of actions / Open Med. Chem. J. 5(2): 70—77.
55. Anilakumar K. R., Kumar G. P., Ilaiyaraja N. 2015. Nutricional, pharmacological and medicinal properties of *Momordica charantia*. — Int. J. Nutr. Food Sci. 4(1): 75—83.
56. Ahmed I., Cummings E., Sharma A. K., Adeghate E., Singh J. 2004. Beneficial effects and mechanism of action of *Momordica charantia* fruit juice in the treatment of streptozotocin-induced diabetes mellitus in rats. — Mol. Cell. Biochem. 261(1): 63—70.
57. Cummings E., Hundal H. S., Wackerhage H., Hope M., Belle M., Adeghate E., Singh J. 2004. *Momordica charantia* fruit juice stimulates glucose and amino acid uptakes in L6 myotubes. — Mol. Cell. Biochem. 261(1—2): 99—104.
58. Wang H. Y., Kan W. C., Cheng T. J., Yu S. H., Chang L. H., Chuu J. J. 2014. Differential antidiabetic effects and mechanism of action of charantin-rich extract of Taiwanese *Momordica charantia* between type 1 and type 2 diabetic mice. — Food Chem. Toxicol. 69(4): 347—356.
59. Mahomoodally M. F., Subratty A. H., Gurib-Fakim A. 2012. Traditional medicinal herbs and food plants have the potential to inhibit key carbohydrate hydrolyzing enzymes *in vitro* and reduce postprandial blood glucose peaks *in vivo*. — Sci. World J. <http://dx.doi.org/10.1100/2012/285284>
60. He Y., Wang X. B., Fan B. Y., Kong L. Y. 2014. Honokiol trimmers and dimmers via biotransformation catalyzed by *Momordica charantia* peroxidase: novel and potent α -glucosidase inhibitors. — Bioorg. Med. Chem. 22(2): 762—771.
61. Hafizur R. M., Kabir N., Chishti S. 2011. Modulation of pancreatic b-cells in neonatally streptozotocin-induced type 2 diabetic rats by the ethanolic extract of *Momordica charantia* fruit pulp. — Nat. Prod. Res. 25(4): 353—367.
62. Keller A. C., Ma J., Kavalier A., He K., Brillantes A. M., Kennelly E. J. 2011. Saponins from the traditional medicinal plant *Momordica charantia* stimulate insulin secretion *in vitro*. — Phytomedicine. 19(1): 32—37.
63. Iseli T. J., Turner N., Zeng X. Y., Cooney G. J., Kraegen E. W., Yao S., Ye Y., James D. E., Ye J. M. 2013. Activation of AMPK by bitter melon triterpenoids involves CaMKKb. — PLoS One. <http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0062309>
64. Wu S. B., Yue G. G., To M. H., Keller A. C., Lau C. B., Kennelly E. J. 2014. Transport in Caco-2 cell monolayers of antidiabetic cucurbitane triterpenoids from *Momordica charantia* fruits. — Planta Med. 80(11): 907—911.
65. Harinantenaina L., Tanaka M., Takaoka S., Oda M., Mogami O., Uchida M., Asakawa Y. 2006. *Momordica charantia* constituents and antidiabetic screening of the isolated major compounds. — Chem. Pharm. Bull. 54(7): 1017—1021.
66. Shih C. C., Lin C. H., Lin W. L. 2008. Effects of *Momordica charantia* on insulin resistance and visceral obesity in mice on high-fat diet. — Diabetes Res. Clin. Pract. 81(2): 134—143.
67. Wang Z. Q., Zhang X. H., Yu Y., Poulev A., Ribnicky D., Floyd Z. E., Cefalu W. T. 2011. Bioactives from bitter melon enhance insulin signaling and modulate acyl carnitine content in skeletal muscle in high-fat diet-fed mice. — J. Nutr. Biochem. 22(11): 1064—1073.
68. Chen P. H., Chen G. C., Yang M. F., Hsieh C. H., Chuang S. H., Yang H. L., Kuo Y. H., Chyuan J. H., Chao P. M. 2012. Bitter melon seed oil-attenuated body fat accumulation in diet-induced obese mice is associated with cAMP-dependent protein kinase activation and cell death in white adipose tissue. — J. Nutr. 142(7): 1197—1204.

69. Gadang V., Gilbert W., Hettiarachchy N., Horax R., Katwa L., Devareddy L. 2011. Dietary bitter melon seed increases peroxisome proliferator-activated receptor-g gene expression in adipose tissue, down-regulates the nuclear factor-kB expression, and alleviates the symptoms associated with metabolic syndrome. — *J. Med. Food.* 14(1): 86—93.
70. Saha S. S., Ghosh M. 2012. Antioxidant and antiinflammatory effect of conjugated linolenic acid isomers against streptozotocin-induced diabetes. — *Br. J. Nutr.* 108(6): 974—983.
71. Chabra G., Dixit A. 2013. Structure modeling and antidiabetic activity of a seed protein of *Momordica charantia* in non-obese diabetic (NOD) mice. — *Bioinform.* 9(15): 766—770.
72. Joseph B., Jini D. 2013. Antidiabetic effects of *Momordica charantia* (bitter melon) and its medicinal potency. — *Asian Pacif. J. Trop. Dis.* 3(1): 93—102.
73. Lo H. Y., Ho T. Y., Lin C., Li C. C., Hsiang C. Y. 2013. *Momordica charantia* and its novel polypeptide regulate glucose homeostasis in mice via binding to insulin receptor. — *J. Agric. Food Chem.* 61(10): 2461—2468.
74. Lo H. Y., Ho T. Y., Li C. C., Chen J. C., Liu J. J., Hsiang C. Y. 2014. A novel insulin receptor-binding protein from *Momordica charantia* enhances glucose uptake and glucose clearance *in vitro* and *in vivo* through triggering insulin receptor signaling pathway. — *J. Agric. Food Chem.* 62(36): 8952—8961.
75. Ukkola O., Santaniemi M. 2002. Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities. — *J. Int. Med.* 251(6): 467—475.
76. Klomann S. D., Mueller A. S., Pallauf J., Krawinkel M. B. 2010. Antidiabetic effects of bitter gourd extracts in insulin-resistant db/db mice. — *Br. J. Nutr.* 104(11): 1613—1620.
77. Zeng K., He Y. N., Yang D., Cao J. Q., Xia X. C., Zhang S. J., Bi X. L., Zhao Y. Q. 2014. New compounds from acid hydrolyzed products of the fruits of *Momordica charantia* L. and their inhibitory activity against protein tyrosine phosphatase 1B. — *Eur. J. Med. Chem.* 81(2): 176—180.
78. Hazarika R., Parida P., Neog B., Yadav R. N. 2012. Binding, energy calculation of GSK-3 protein of human against some antidiabetic compounds of *Momordica charantia* L. (Bitter melon). — *Bioinform.* 8(6): 251—254.
79. Hussan F., Teoh S. L., Muhamad N., Mazlan M., Latiff A. A. 2014. *Momordica charantia* ointment accelerates diabetic wound healing and enhances transforming growth factor-b expression. — *J. Wound. Care.* 23(8): 404—407.
80. Manjappa B., Gangaraju S., Girishet K. S., Kemparaju K., Gonchigar S. J., Shankar R. L., Shinde M., Sannanigaiah D. 2014. *Momordica charantia* seed extract exhibits strong anticoagulant effect by specifically interfering in intrinsic pathway of blood coagulation and dissolves fibrin clot. — *Blood Coagul. Fibrinol.* 11(9): 921—925.
81. França E. L., Ribeiro E. B., Scherer E. F., Cantarini D. G., Pessôa R. S., França F. L., Honorio-França A. C. 2014. Effects of *Momordica charantia* L. on the blood rheological properties in diabetic patients. *Biomed. Res. Int.* <http://dx.doi.org/10.1155/2014/840379>
82. Nerurkar P. V., Johns L. M., Buesa L. M., Kipyakwai G., Volper E., Sato R., Shah P., Feher D., Williams P. G., Nerurkar V. R. 2011. *Momordica charantia* (bitter melon) attenuates high-fat diet-associated oxidative stress and neuroinflammation. — *J. Neuroinflamm.* 8(64) <http://www.jneuroinflammation.com/content/8/1/64>
83. Malik Z. A., Singh M., Sharma P. L. 2011. Neuroprotective effect of *Momordica charantia* in global cerebral ischemia and reperfusion induced neuronal damage in diabetic mice. — *J. Ethnopharmacol.* 133(2): 729—734.
84. Kumar G. S., Shetty A. K., Salimat P. V. 2008. Modulatory effect of bitter gourd (*Momordica charantia* Linn.) on alterations in kidney heparin sulfate in streptozotocin-induced diabetic rats. — *J. Ethnopharmacol.* 115(2): 276—283.
85. Ooi C. P., Yassin Z., Hamid T. A. 2012. *Momordica charantia* for type 2 diabetes mellitus. — *Cochrane Database Syst. Rev.* 15(8): 834—840.

86. Habicht S. D., Ludwig C., Yang R. Y., Krawinkel M. B. 2014. *Momordica charantia* and type 2 diabetes: from in vitro to human studies. — *Curr. Diabetes Rev.* 10(1): 48—60.
87. Roberts K. T. 2011. The potential of fenugreek (*Trigonella foenum-graecum*) as a functional food and nutraceutical and its effects on glycemia and lipidemia. — *J. Med. Food.* 14(12): 1485—1489.
88. Moorthy R., Prabhu K. M., Murthy P. S. 2010. Mechanism of antidiabetic action, efficacy and safety profile of GII purified from fenugreek (*Trigonella foenum-graecum* L.) seeds in diabetic animals. — *Ind. J. Exp. Biol.* 48(11): 1119—1122.
89. Bera T. K., Ali K. M., Jana K., Ghosh A., Ghosh D. 2013. Protective effect of aqueous extract of seed of *Psoralea corylifolia* (Somraji) and seed of *Trigonella foenum-graecum* L. (Methi) in streptozotocin-induced diabetic rat: a comparative evaluation. — *Pharmacogn. Res.* 5(4): 277—285.
90. Marzouk M., Soliman A. M., Omar T. Y. 2013. Hypoglycemic and antioxidative effects of fenugreek and terms seeds powder in streptozotocin-diabetic rats. — *Eur. Rev. Med. Pharmacol. Sci.* 17(4): 559—565.
91. Puri D., Prabhu K. M., Murthy P. S. 2012. Antidiabetic effect of GII compound purified from fenugreek (*Trigonella foenum-graecum* L.) seeds in diabetic rabbits. — *Ind. J. Clin. Biochem.* 27(1): 21—27.
92. Hamza N., Berke B., Cheze C., Le Garrec R., Umar A., Agli A. N., Lassalle R., Jové J., Gin H., Moore N. 2012. Preventive and curative effect of *Trigonella foenum-graecum* L. seeds in C57BL/6J models of type 2 diabetes induced by high-fat diet. — *J. Ethnopharmacol.* 142(2): 516—522.
93. Zhou J., Chan L., Zhou S. 2012. Trigonelline: a plant alkaloid with therapeutic potential for diabetes and central nervous system disease. — *Curr. Med. Chem.* 19(12): 3523—3531.
94. Zhou J., Zhou S. 2012. Protection of trigonelline on experimental diabetic peripheral neuropathy. *Evid. Based. Complement. Alternat. Med.* 2012:164219.
95. Haeri M. R., Limaki H. K., White C. J., Whit K. N. 2012. Non-insulin dependent anti-diabetic activity of (2S, 3R, 4S) 4-hydroxyisoleucine of fenugreek (*Trigonella foenum-graecum*) in streptozotocin-induced type I diabetic rats. — *Phytomedicine.* 19(7): 571—574.
96. Singh A. B., Tamarkar A. K., Narender T., Srivastava A. K. 2010. Antihyperglycaemic effect of an unusual amino acid (4-hydroxyisoleucine) in C57BL/KsJ-db/dbmice. — *Nat. Prod. Res.* 24(3): 258—265.
97. Losso J. N., Holliday D. L., Finley J. W., Martin R. J., Rood J. C., Yu Y., Greenway F. L. 2009. Fenugreek bread: a treatment for diabetes mellitus. — *J. Med. Food.* 12(5): 1046—1049.
98. Srinivasan K. 2014. Antioxidant potential of spices and their active constituents. — *Crit. Rev. Food. Sci. Nutr.* 54(3): 352—372.
99. Sankar P., Subhashree S., Sudharani S. 2012. Effect of *Trigonella foenum-graecum* seed powder on the antioxidant levels of high fat diet and low dose streptozotocin-induced type II diabetic rats. — *Eur. Rev. Med. Pharmacol. Sci.* 16, Suppl. 3: 10—17.
100. Uemura T., Hirai S., Mizoguchi N., Goto T., Lee J. Y., Taketani K., Nakano Y., Shono J., Hoshino S., Tsuge N., Narukami T., Takahashi N., Kawada T. 2010. Diosgenin present in fenugreek improves glucose metabolism by promoting adipocyte differentiation and inhibiting inflammation in adipose tissues. — *Mol. Nutr. Food Res.* 54(11): 1596—1608.
101. Uemura T., Goto T., Kang M. S., Mizoguchi N., Hirai S., Lee J. Y., Nakano Y., Shono J., Hoshino S., Taketani K., Tsuge N., Narukami T., Makishima M., Takahashi N., Kawada T. 2011. Diosgenin, the main aglycon of fenugreek, inhibits LXRA activity in HepG2 cells and decreases plasma and hepatic triglycerides in obese diabetic mice. — *J. Nutr.* 141(1): 17—23.
102. Gupta S. K., Kumar B., Nag T. C., Srinivasan B. P., Srivastava S., Gaur S., Saxena R. 2014. Effects of *Trigonella foenum-graecum* (L.) on renal oxidative stress, and proinflammatory and angiogenic molecular biomarkers in streptozotocin-induced diabetic rats. — *Mol. Cell. Biochem.* 388(2): 19—24.

103. Hamden K., Jaouadi B., Carreau S., Aouidet A., El-Fazaa S., Gharbi N., Elfeki A. 2010. Potential protective effect on key steroidogenesis and metabolic enzymes and sperm abnormalities by fenugreek steroids in testis and epididymis of surviving diabetic rats. — Arch. Physiol. Biochem. 116(3): 146—155.
104. Kumar P., Kale R. K., Baquer N. Z. 2012. Antihyperglycemic and protective effects of *Trigonella foenum-graecum* seed powder on biochemical alterations in alloxan-diabetic rats. — Eur. Rev. Med. Pharmacol. Sci. 16, Suppl. 3: 18—27.
105. Baquer N. Z., Kumar P., Taha A., Kale R. K., Cowsik S. M., McLean P. 2011. Metabolic and molecular action of *Trigonella foenum-graecum* (fenugreek) and trace metals in experimental diabetic tissues. — J. Biosci. 36(2): 383—396.